| An Overview of the Treatment of Less Common Non–Lactose‐Fermenting Gram‐Negative Bacteria HK Spencer, SL Spitznogle, J Borjan, SL Aitken Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (9 …, 2020 | 31 | 2020 |
| High levels of common cold coronavirus antibodies in convalescent plasma are associated with improved survival in COVID-19 patients U Greenbaum, K Klein, F Martinez, J Song, PF Thall, JL Ramdial, ... Frontiers in immunology 12, 675679, 2021 | 25 | 2021 |
| Activity of ceftazidime-avibactam alone and in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae in a tandem in vitro time-kill/in vivo Galleria … J Borjan, KA Meyer, RK Shields, E Wenzler International journal of antimicrobial agents 55 (1), 105852, 2020 | 24 | 2020 |
| Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period. H Dagher, AM Chaftari, IM Subbiah, AE Malek, Y Jiang, P Lamie, ... Elife 12, 2023 | 15 | 2023 |
| Significant publications on infectious diseases pharmacotherapy in 2018 J Borjan, AJ Gonzales-Luna, TJ Carlson, NA Finch, AP Mitchell, ... Journal of Pharmacy Practice 32 (5), 546-557, 2019 | 9 | 2019 |
| International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship II Raad, R Hachem, N Masayuki, T Datoguia, H Dagher, Y Jiang, ... elife 12, e81127, 2023 | 5 | 2023 |
| 300. long COVID in cancer patients: Preponderance of symptoms in majority of patients over long time period H Dagher, A Malek, AM Chaftari, IM Subbiah, Y Jiang, P Lamie, ... Open forum infectious diseases 8 (Supplement_1), S256-S257, 2021 | 5 | 2021 |
| High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant WC Shropshire, BT Endres, J Borjan, SL Aitken, WC Bachman, ... Journal of Antimicrobial Chemotherapy 78 (10), 2442-2450, 2023 | 3 | 2023 |
| Successful outcomes of severe COVID-19 in patient with chronic lymphocytic leukemia: diagnostic challenges in immunocompromised hosts AE Malek, C Gutierrez, VE Mulanovich, J Botdorf, RF Chemaly, S Shah, ... Mediterranean Journal of Hematology and Infectious Diseases 12 (1), 2020 | 3 | 2020 |
| 2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia. J Borjan, SA Shelburne, MM Bhatti, SL Aitken Open Forum Infectious Diseases 6, 2019 | 2 | 2019 |
| 2451. Synergistic activity of ceftazidime–avibactam in combination with polymyxin B against carbapenem-resistant Klebsiella pneumoniae J Borjan, E Wenzler Open Forum Infectious Diseases 5 (Suppl 1), S733, 2018 | 2 | 2018 |
| Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185 A Kawai, WC Shropshire, M Suzuki, J Borjan, SL Aitken, WC Bachman, ... Mbio, e02874-23, 2024 | 1 | 2024 |
| International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Survivorship I Raad, R Hachem, N Masayuki, T Datoguia, H Dagher, Y Jiang, ... medRxiv, 2022.08. 25.22279181, 2022 | 1 | 2022 |
| 356. The Role of Procalcitonin in Antimicrobial Stewardship Among Cancer Patients Admitted with COVID-19 H Dagher, AM Chaftari, RY Hachem, Y Jiang, A Malek, NJD Garnes, ... Open forum infectious diseases 8 (Suppl 1), 282, 2021 | 1 | 2021 |
| # AMRrounds: a systematic educational approach for navigating bench to bedside antimicrobial resistance E Liu, AM Prinzi, J Borjan, SL Aitken, PA Bradford, WF Wright JAC-Antimicrobial Resistance 5 (4), dlad097, 2023 | | 2023 |
| Procalcitonin for antimicrobial stewardship among cancer patients admitted with COVID-19 H Dagher, AM Chaftari, P Mulanovich, Y Jiang, R Hachem, AE Malek, ... Elife 11, e81151, 2022 | | 2022 |
| Long COVID in Cancer patients: Preponderance of Symptoms in Majority of Patients over Long Time Period (preprint) H Dagher, AM Chaftari, IM Subbiah, AE Malek, Y Jiang, P Lamie, ... | | 2022 |
| 22. International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-19: Impact of Risk Factors and Treatment Modalities on Outcome RY Hachem, AM Chaftari, N Masayuki, N Hamerschlak, H Dagher, ... Open forum infectious diseases 8 (Supplement_1), S15-S15, 2021 | | 2021 |
| 605. Identification of a Novel CMY-Variant Enzyme in a Clinical Escherichia coli Strain with Treatment-Emergent Ceftazidime–Avibactam Resistance SL Aitken, SL Aitken, BT Endres, A Khan, WC Shropshire, J Borjan, ... Open Forum Infectious Diseases 6 (Supplement_2), S283-S283, 2019 | | 2019 |
